Nervous system

BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research

Wednesday, May 27, 2020 - 12:25pm

"The investigational NurOwn technology platform currently in Phase 3 and Phase 2 for ALS and progressive MS, respectively, have life changing potential.

Key Points: 
  • "The investigational NurOwn technology platform currently in Phase 3 and Phase 2 for ALS and progressive MS, respectively, have life changing potential.
  • This has been the most significant factor in my decision to join Brainstorm," said Dr. Stacy R Lindborg.
  • I look forward to seeing NurOwn and the Company's pipeline advance across all stages of clinical development."
  • Her experience includes global organization design and development at two of the world's leading neurology companies, including substantial corporate builds.

Axial Biotherapeutics to Present at the Jefferies Virtual Global Healthcare Conference

Wednesday, May 27, 2020 - 1:01pm

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET.

Key Points: 
  • Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the David H. Donabedian, Ph.D., Co-founder and Chief Executive Officer of Axial Biotherapeutics will present a company overview at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, 2020 at 4:30 PM ET.
  • Axial Biotherapeutics is a clinical stage biotechnology company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of central nervous system (CNS) and other gut-derived diseases.
  • The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinsons Disease and Autism Spectrum Disorder.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005109/en/

Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting

Tuesday, May 26, 2020 - 10:15pm

These findings were presented during the 6th Congress of the European Academy of Neurology (EAN).

Key Points: 
  • These findings were presented during the 6th Congress of the European Academy of Neurology (EAN).
  • "The results being presented at EAN suggest that dyskinesia is observed more often in patients with baseline dyskinesia before istradefylline was added to the treatment regimen and that the overall efficacy of istradefylline was not affected by patients' baseline status.
  • While these data provide further information, physicians should continue to monitor patients for dyskinesia or exacerbation of existing dyskinesia during NOURIANZ treatment.
  • Impact of Baseline Dyskinesia on the Safety and Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, in Patients with Parkinson's Disease: a Pooled Analysis of 8 Clinical Studies.

Research Report with COVID-19 Forecasts - Neuropathy Pain Treatment Market 2020-2024 | Presence Of Large Patient Pool To Boost Growth | Technavio

Tuesday, May 26, 2020 - 9:00pm

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322

Key Points: 
  • To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR43322
    Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources.
  • Our neuropathy pain treatment market report covers the following areas:
    This study identifies the growing focus on the development of drugs for the treatment of diabetic neuropathy pain as one of the prime reasons driving the neuropathy pain treatment market growth during the next few years.
  • We provide a detailed analysis of around 25 vendors operating in the neuropathy pain treatment market, including some of the vendors such as Abbott Laboratories, Assertio Therapeutics Inc., AstraZeneca Plc, Baxter International Inc., Eli Lilly and Co., Endo International Plc, Johnson & Johnson, Pfizer Inc., and Sanofi Backed with competitive intelligence and benchmarking, our research reports on the neuropathy pain treatment market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Register for a free trial today and gain instant access to 17,000+ market research reports.

Novaremed Announces IND Submitted to U.S. FDA for Phase 2 Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy; Also Announces the Appointment of Three New Board Members

Monday, May 25, 2020 - 5:30pm

Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019.

Key Points: 
  • Novaremed had received initial feedback from the FDA during a Pre-IND meeting held on July 24, 2019.
  • The Phase 2 study, designed as a randomized, double-blind, placebo-controlled study, will enroll patients experiencing neuropathic pain caused by Diabetes Mellitus.
  • We look forward to launching this Phase 2 study as soon as possible.
  • Novaremed also announced today the appointment of three new members to the companys board of directors, effective May 14, 2020.

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Resources Available from the Multiple Sclerosis Association of America Amidst the COVID-19 Pandemic

Thursday, May 21, 2020 - 2:25pm

MSAAhas made several revisions to the MRI Access Fund as well as to our Cooling and Equipment Distribution programs.

Key Points: 
  • MSAAhas made several revisions to the MRI Access Fund as well as to our Cooling and Equipment Distribution programs.
  • To learn more about the free resources pertaining to COVID-19 that are available from MSAA, please visit https://mymsaa.org/covid .
  • The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support.
  • Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord.

World Neuropathy Pain Treatment Market Analysis 2020, Featuring Key Players Assertio Therapeutics Inc., Endo International Plc and Pfizer - ResearchAndMarkets.com

Thursday, May 21, 2020 - 1:04pm

The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

Key Points: 
  • The report on the neuropathy pain treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
  • The neuropathy pain treatment market analysis includes type segment and geographic landscape.
  • The neuropathy pain treatment market covers the following areas:
    Neuropathy pain treatment market industry analysis.
  • Also, the neuropathy pain treatment market analysis report includes information on upcoming trends and challenges that will influence market growth.

Colorado artist 3D prints ear guards to help medical workers

Wednesday, May 20, 2020 - 3:02pm

Healthcare workers are wearing layers upon layers of gear to ensure that they are protecting themselves, patients, and others when providing care.

Key Points: 
  • Healthcare workers are wearing layers upon layers of gear to ensure that they are protecting themselves, patients, and others when providing care.
  • Southwell's idea for 3D printed ear guards to accompany medical masks came from a combination of peers, social media groups in the 3D printing space, and a Boy Scout Quinn Callander , who crafted a model for the guards.
  • Ian started 3D printing ear guards with grooved "security straps" to ensure masks aren't rubbing on the face of medical workers all day.
  • The hope is that these ear guards relieve some of the physical stress of wearing masks that make direct contact with the ears and face.

New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression

Wednesday, May 20, 2020 - 2:00pm

Moreover, the study reconfirmed that adjunctive VNS Therapy significantly lowers suicidality, a very important and key factor when considering the overall positive impact on the lives of patients and their loved ones.

Key Points: 
  • Moreover, the study reconfirmed that adjunctive VNS Therapy significantly lowers suicidality, a very important and key factor when considering the overall positive impact on the lives of patients and their loved ones.
  • The study was conducted with a patient population of 156 TRBD patients with 97 in the adjunctive VNS Therapy group and 59 in the TAU group.
  • The study drew the conclusion that adjunctive VNS Therapy is an efficacious antidepressant treatment for patients with TRBD.
  • The effects of vagus nerve stimulation on the course and outcomes of patients with bipolar disorder in a treatment-resistant depressive episode: a 5-year prospective registry.